These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27465032)

  • 1. Physiological and Metabolic Changes During the Transition from Hyperthyroidism to Euthyroidism in Graves' Disease.
    Chng CL; Lim AY; Tan HC; Kovalik JP; Tham KW; Bee YM; Lim W; Acharyya S; Lai OF; Chong MF; Yen PM
    Thyroid; 2016 Oct; 26(10):1422-1430. PubMed ID: 27465032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic effects of brown fat in transitioning from hyperthyroidism to euthyroidism.
    Sun L; Goh HJ; Verma S; Govindharajulu P; Sadananthan SA; Michael N; Jadegoud Y; Henry CJ; Velan SS; Yeo PS; Lee Y; Lim BSP; Liew H; Chew CK; Quek TPL; Abdul Shakoor SAKK; Hoi WH; Chan SP; Chew DE; Dalan R; Leow MKS
    Eur J Endocrinol; 2021 Aug; 185(4):553-563. PubMed ID: 34342595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolite Changes during the Transition from Hyperthyroidism to Euthyroidism in Patients with Graves' Disease.
    Lee HY; Sim BC; Nga HT; Moon JS; Tian J; Linh NT; Ju SH; Choi DW; Setoyama D; Yi HS
    Endocrinol Metab (Seoul); 2022 Dec; 37(6):891-900. PubMed ID: 36604959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Swedish Patients with Graves' Hyperthyroidism Is Associated with Changes in Acylcarnitine Levels.
    Al-Majdoub M; Lantz M; Spégel P
    Thyroid; 2017 Sep; 27(9):1109-1117. PubMed ID: 28699427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term Change in Resting Energy Expenditure and Body Compositions in Therapeutic Process for Graves' Disease.
    Hayashi A; Takano K; Kawakami Y; Hitomi M; Ohata Y; Suzuki A; Kamata Y; Shichiri M
    Intern Med; 2020; 59(15):1827-1833. PubMed ID: 32741892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight homeostasis & its modulators in hyperthyroidism before & after treatment with carbimazole.
    Dutta P; Bhansali A; Walia R; Khandelwal N; Das S; Masoodi SR
    Indian J Med Res; 2012 Aug; 136(2):242-8. PubMed ID: 22960891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hunger-satiety signals in patients with Graves' thyrotoxicosis before, during, and after long-term pharmacological treatment.
    Röjdmark S; Calissendorff J; Danielsson O; Brismar K
    Endocrine; 2005 Jun; 27(1):55-61. PubMed ID: 16077172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A patient-specific treatment model for Graves' hyperthyroidism.
    Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S
    Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.
    Kallner G; Vitols S; Ljunggren JG
    J Intern Med; 1996 Jun; 239(6):525-9. PubMed ID: 8656146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.
    Harper L; Chin L; Daykin J; Allahabadia A; Heward J; Gough SC; Savage CO; Franklyn JA
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):671-5. PubMed ID: 15163328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the pharmacological management of hyperthyroidism due to Graves' disease.
    Bartalena L; Tanda ML; Bogazzi F; Piantanida E; Lai A; Martino E
    Expert Opin Pharmacother; 2005 Jun; 6(6):851-61. PubMed ID: 15952916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations of adiponectin in patients with hyperthyroidism before and after control of thyroid function.
    Hsieh CJ; Wang PW
    Endocr J; 2008 Jul; 55(3):489-94. PubMed ID: 18469483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves' disease.
    van Soestbergen MJ; van der Vijver JC; Graafland AD
    J Endocrinol Invest; 1992 Dec; 15(11):797-800. PubMed ID: 1283983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
    Žarković M; Wiersinga W; Perros P; Bartalena L; Donati S; Okosieme O; Morris D; Fichter N; Lareida J; Daumerie C; Burlacu MC; Kahaly GJ; Pitz S; Beleslin B; Ćirić J; Ayvaz G; Konuk O; Törüner FB; Salvi M; Covelli D; Curro N; Hegedüs L; Brix T;
    J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Differential Effects of Propylthiouracil and Methimazole as Graves' Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial.
    Wisnu W; Alwi I; Nafrialdi N; Harimurti K; Pemayun TGD; Jusman SWA; Santoso DIS; Harahap AR; Suwarto S; Subekti I
    Front Endocrinol (Lausanne); 2021; 12():796194. PubMed ID: 34987480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid function and immunological activity during and after medical treatment of Graves' disease.
    Gossage AA; Crawley JC; Copping S; Hinge D; Himsworth RL
    Clin Endocrinol (Oxf); 1983 Jul; 19(1):87-96. PubMed ID: 6137296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.